Biotech firm 21st.BIO unveils pilot plant facility to accelerate bioproduction upscaling

21st.BIO, a Danish bioproduction company, has unveiled a new pilot plant facility designed to support businesses in upscaling their bioproduction processes. The company provides services ranging from strain construction to industrial production upscaling to customers worldwide, aiming to help them scale up more efficiently and cost-effectively. The pilot facility will enable customers to optimize their processes and collaborate with 21st.BIO experts, ultimately reducing the risk of costly failures.

The pilot facility is strategically located within the same building as 21st.BIO’s strain development laboratories, allowing for seamless collaboration between the company and customer teams. With over 3,000 liters of fermentation capacity, the facility is equipped to handle a wide range of applications, including nutrition, food and beverages, agriculture, biomaterials, and biopharma.

21st.BIO’s pilot plant is part of Denmark’s bioproduction leadership, a country home to pioneers like Novo Nordisk and Novozymes. The European Commission has also recognized the potential of the biotech sector, presenting a series of actions to boost the sector in the EU, including simplified regulatory frameworks and faster access to market. The company’s founders aim to enable the building of large-scale protein facilities across the world, addressing the challenge of translating bio innovations into commercial success.

TAGGED:
Share This Article